Results 101 to 110 of about 34,135 (204)

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

Opposing roles of DGAT‐mediated lipid droplet biogenesis in the regulation of ferroptosis sensitivity

The FEBS Journal, EarlyView.
Ferroptosis is driven by unrestricted peroxidation of polyunsaturated fatty acyl (PUFA) chains in membrane phospholipids. In triple‐negative breast cancer cells, lipid droplets (LDs) sequester dietary PUFAs, limiting their incorporation into membrane phospholipids, preventing mitochondrial damage, and reducing lipid peroxidation and ferroptosis.
Ana Kump, Leja Perne, Špela Koren, Eva Jarc Jovičić, Nastja Feguš, Carina Pinto Kozmus, Michele Wölk, Kristyna Brejchova, Maria Fedorova, Ondrej Kuda, Toni Petan   +10 more
wiley   +1 more source

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Contemporary Clinical Trials Communications
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and ...
Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp   +16 more
doaj   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core  

Real‐world prevalence of PD‐L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Histopathology, EarlyView.
In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso‐Sousa, Nagi S El Saghir, Rebecca Dent, Nataša Medić‐Milijić, Gyungyub Gong, Shahin Sayed, Tu Thai Anh, Alisan Zirtiloglu, Götz Hartleben, Paula Toro, Iman Estaytieh, Enya Weber, Regula Deurloo, João Mouta, Lazar Popovic   +16 more
wiley   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, Volume 86, Issue 6, Page 689-696, May 2026.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

Treatment outcomes of patients with BRCA-mutated, recurrent ovarian cancer in University Hospital Center Split

Libri Oncologici, 2022
Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with platinum-sensitive, BRCA-mutated, recurrent ovarian cancer treated at the University Hospital Center Split in the period from June 2016 to ...
Branka Petrić-Miše, Mirko Pešo, Darijo Hrepić, Vesna Telesmanić-Dobrić, Eduard Vrdoljak   +4 more
doaj  

Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib [PDF]

, 2018
Upon DNA binding the poly(ADP-ribose) polymerase family of enzymes (PARPs) add multiple ADP-ribose subunits to themselves and other acceptor proteins.
Albert, Ali, Ame, Amit Nathubhai, Audebert, Barkauskaite, Beck, Benhur, Benjamin, Blenn, Boehler, Boulton, Braun, Bridges, Brochu, Bryant, Bryant, Bryant, Calabrese, Chalmers, Chang, Chang, Chang, Chow, Cortes, deMurcia, Ding, Dominic I. James, Donawho, Drean, Dungey, Dungey, Efimova, El-Khamisy, Emma Grant, Erdelyi, Fabbro, Fathers, Feng, Feng, Feng, Fisher, Godon, Gravells, Ha, Helen E. Bryant, Huang, Illuzzi, James, James Neale, Kate M. Smith, Khan, Kim, Le Page, Lee, Lomax, Martin, Medvedeva, Min, Miwa, Morrison, Mueller, Nakadate, Nathubhai, Noel, Okano, Oplustil O'Connor, Ozaki, Polly Gravells, Ray Chaudhuri, Rothkamm, Rulten, Rulten, Saleh-Gohari, Schlicker, Schreiber, Senra, Shall, Shelton, Shirai, Shirai, Slade, Strom, Sugimura, Tripathi, Trucco, Venere, Wang, Wang, Wang, Wieler, Yang, Yeh, Yoshikawa, Zhu   +94 more
core   +2 more sources

The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Thalidomide serves as a molecular nexus linking chemistry and biology: advances in synthesis and structural understanding enable protein degradation technologies, while its immunomodulatory activity underpins anti‐inflammatory and anticancer therapies.
Konstantina Nikovia, Michael Kapsalis, Michael Georgoulakis, Athanasios Panousis, Constantinos G. Neochoritis   +4 more
wiley   +1 more source

Patient derived xenograft models of small-cell lung cancer provide molecular insights into mechanisms of chemotherapy cross-resistance [PDF]

, 2018
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung cancer the median survival time of 14.5 months has seen little improvement over the last four ...
Myers, David Thomas
core